Endocrine therapeutic agents, including selective ER modulators, selective ER degraders, and aromatase inhibitors, provide high therapeutic efficacy by intervening in ERα-dependent growth of breast cancer cells. The gene discussed is ESR1; the disease is breast carcinoma.